Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 25 of the 51 sources its claims cite were checked for support.
Abstract
OBJECTIVE: Melatonin use quintupled in recent decades. The common melatonin receptor 1B gene (MTNR1B) variant increases risk of type 2 diabetes, raising concerns about melatonin’s adverse metabolic effects and highlighting the need for a genotype-based personalized approach. We aimed to comprehensively characterize the actions of melatonin on glucose homeostasis, including first- and second-phase β-cell responsivity to glucose, β-cell negative feedback by exogeneous insulin, insulin sensitivity, and whether such effects are stronger in MTNR1B G-allele risk carriers compared with noncarriers. RESEARCH DESIGN AND METHODS: Twenty-one healthy participants of European ancestry were studied in a randomized, double-blind, placebo-controlled, crossover trial, including 10 MTNR1B risk carriers and 11 noncarriers. Each participant underwent a highly controlled 5-day laboratory protocol, during which they received 5 mg oral melatonin or placebo in randomized order on two nonconsecutive days. Glycemic dynamics were assessed using insulin-modified intravenous glucose tolerance tests with minimal-model analysis. RESULTS: Melatonin worsened glucose tolerance and reduced early C-peptide responses in risk allele carriers (vs. placebo: 11.7% [95% CI 1.0–22.3] and −19.2% [−33.9 to −1.2], respectively; Padj < 0.05) but not in noncarriers. In carriers, impairments stemmed from a 40% (−52.4 to −24.3; Padj = 0.0003) suppression of glucose-stimulated first-phase β-cell responsivity, along with a slower insulin-induced decline in second-phase insulin secretion rate (64.3% [23.1–119.2]; Padj = 0.001). In carriers, melatonin also prevented exogenous insulin-induced hypoglycemia compared with placebo (zero vs. seven events, P = 0.001), but not in noncarriers. CONCLUSIONS: These findings identify blunted β-cell responsivity to glucose and dysregulated insulin negative feedback as key mechanisms linking melatonin signaling to diabetes risk.
Overview
CoChat Summary
TL;DR
In a randomized, double-blind, placebo-controlled crossover trial of 21 healthy European-ancestry adults, 5 mg oral melatonin acutely worsened glucose tolerance and early insulin/C-peptide responses only in *MTNR1B* risk allele carriers. The impairments were linked to reduced first-phase β-cell responsivity to glucose and slower insulin-induced decline in second-phase insulin secretion rate, with fewer exogenous insulin-induced hypoglycemic events in carriers.
Key findings
- In *MTNR1B* risk allele carriers, melatonin increased 3-h glucose iAUC by 11.7% (95% CI 1.0–22.3; Padj = 0.03) versus placebo; noncarriers showed no significant change (−5.0% [−14.1 to 4.1], Padj = 0.35).
- Early 20-min C-peptide iAUC decreased by 19.2% (−33.9 to −1.2; Padj = 0.04) in carriers, with a 25.2% insulin iAUC decrease (−44.9 to 1.4; Padj = 0.06); noncarriers had no significant changes.
- First-phase β-cell responsivity to glucose (Φ1) was reduced by melatonin overall (−25.6% [−35.2 to −14.6]; P = 0.0003), driven by carriers (−39.9% [−52.4 to −24.3]; Padj < 0.0001) versus noncarriers (−7.9% [−26.1 to 14.9]; Padj = 0.62).
- In carriers, melatonin prolonged the half-time of second-phase insulin secretion rate decline by 64.3% (23.1–119.2; Padj = 0.001) and prevented exogenous insulin-induced level 1 hypoglycemia (zero vs. seven events, P = 0.001); noncarriers showed no significant T1/2 change (13.3% [−34.1 to 94.5], Padj = 0.41) or hypoglycemia difference (two vs. five events, P = 0.20).
Methods
- Randomized, double-blind, placebo-controlled crossover trial: 21 healthy nonsmoking European-ancestry adults aged 21–55 years, BMI 20–35 kg/m², including 10 *MTNR1B* risk carriers and 11 noncarriers; 5-day in-laboratory protocol with fixed sleep/wake schedule, 5 mg oral melatonin or placebo on two nonconsecutive days, and 48-h washout.
- Insulin-modified frequently sampled intravenous glucose tolerance tests (FSIGT) with minimal-model analysis estimated insulin sensitivity, glucose effectiveness, β-cell responsivity indices (Φ1, Φ2, Φt), insulin secretory rate, disposition index, insulin clearance, and hepatic insulin extraction.
- Mixed-model ANOVA on log-transformed data with treatment, carrier status, and interaction terms; Šídák adjustment for multiple comparisons; χ² test for hypoglycemic events (<70 mg/dL).
Limitations
- Stated: modest study duration and sample size; enrollment restricted to adults of European ancestry to reduce uncertainty and variability, limiting generalizability; participants were healthy individuals without diabetes, so the study did not test long-term melatonin administration or effects in patient populations.
- Stated: the study aimed to test acute interaction effects of melatonin and *MTNR1B* genotype, not whether long-term melatonin causes type 2 diabetes or improves glucose control.
- Evident from the text: the small sample (21 total; 10 carriers, 11 noncarriers) limits precision and subgroup analyses; findings may not generalize to other ancestries, diabetes populations, or chronic dosing; the afternoon FSIGT timing may differ from prior morning studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 2 Not valid · 13 Not checked · 69 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The common melatonin receptor 1B gene (MTNR1B) variant increases risk of type 2 diabetes”
- Also stated in: § Introduction · plain
“genome-wide association studies (GWAS) identifying genetic variation in MTNR1B (encoding melatonin receptor 2, also known as MT2) as a risk locus for type 2 diabetes (T2D).”
What the sources say
- Not checked — no full text of the sourcecites [6] Karamitri, 2019, Melatonin in type 2 diabetes mellitus and obesity, Nat Rev Endocrinol source
- Supportedcites [7] Garaulet, 2020, Melatonin effects on glucose metabolism: time to unlock the controversy, Trends Endocrinol Metab source
The section “Is melatonin deleterious for T2D?” states that the common MTNR1B rs10830963 risk variant is associated with increased type 2 diabetes risk. This supports the claim as a statement of genetic risk association. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Notably, the common intronic gain-of-function variant rs10830963 G in MTNR1B shows the strongest association among known single nucleotide polymorphisms with elevated fasting glucose and impaired insulin secretion (6,7)”
What the sources say
- Not checked — no full text of the sourcecites [6] Karamitri, 2019, Melatonin in type 2 diabetes mellitus and obesity, Nat Rev Endocrinol source
- Partly supportedcites [7] Garaulet, 2020, Melatonin effects on glucose metabolism: time to unlock the controversy, Trends Endocrinol Metab sourceExperimental — accuracy not yet measured
In “Is melatonin deleterious for T2D?” (page not provided), the paper links rs10830963 to impaired fasting glucose and decreased insulin secretion. It says the common MTNR1B risk allele has *one of the strongest* effects among known T2D-risk SNPs on lowering the disposition index—not the single strongest association with both elevated fasting glucose and impaired insulin secretion. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The sample size was based on our prior work (14), with an effect size of 1.24 for the difference in 2-h glucose area under the curve (AUC) following a morning oral glucose tolerance test (OGTT) after melatonin administration as compared with placebo between heterozygous carriers and noncarriers of the MTNR1B common variant.”
What the sources say
- Partly supportedcites [14] Rubio-Sastre, 2014, Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening, Sleep sourceExperimental — accuracy not yet measured
The Calculations and Statistical Analysis section describes 120-minute glucose AUC after OGTT, and Table 1 reports a morning melatonin-versus-placebo difference. Neither passage reports an effect size of 1.24 or a comparison between heterozygous carriers and noncarriers of the MTNR1B variant; searches for those terms found no such analysis. Page numbers were not available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“First-phase insulin secretion serves to rapidly inhibit hepatic glucose production (31).”
What the sources say
- Supportedcites [31] Cherrington, 2002, Physiological consequences of phasic insulin release in the normal animal, Diabetes source
The paper’s summary in Section 3 states that first-phase insulin release rapidly inhibits glucose production, and the same passage identifies the liver as the site of that action. Another Section 3 passage explicitly says it rapidly inhibits glucose production by the liver. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Over time, both mechanisms, recurrent postprandial hyperglycemia and prolonged insulin secretion, may promote β-cell stress and accelerate progression from impaired glucose tolerance to overt T2D (34,35).”
What the sources say
- Partly supportedcites [34] Fonseca, 2011, Endoplasmic reticulum stress and pancreatic β-cell death, Trends Endocrinol Metab sourceExperimental — accuracy not yet measured
In “Causes of ER-stressed β cells” (page unavailable), the paper says high glucose and increased insulin biosynthesis can cause β-cell ER stress. In “ER stress: Link between β cell loss and impaired function in common forms of diabetes” (page unavailable), it proposes that this stress contributes to the transition from pre-diabetes to overt diabetes. It does not specifically establish recurrent postprandial hyperglycemia, prolonged insulin secretion, or progression from impaired glucose tolerance; its clinical example concerns impaired fasting glucose. (LLM, conf=0.85)
- Partly supportedcites [35] Chang-Chen, 2008, β-Cell failure as a complication of diabetes, Rev Endocr Metab Disord sourceExperimental — accuracy not yet measured
The Glucotoxicity and ER Stress sections (page numbers unavailable) link chronic hyperglycemia and increased biosynthetic demand to β-cell dysfunction and stress. They do not specifically establish that recurrent postprandial hyperglycemia or prolonged insulin secretion accelerates progression from impaired glucose tolerance to overt type 2 diabetes. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
30 more claims · 1 with their cited sources checked
Create a free account to see all 100 claims and every source verdict.
- Probably not a substantial claim. 32
- It may state two separate claims as one. 44
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results
“−0.5 [−5.6 to –4.6] mg/dL”
§ Results
“Padj = 0.97”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RESULTS
“40% (−52.4 to −24.3; Padj = 0.0003)”
§ Results
“39.9% (−52.4 to −24.3, Padj < 0.0001)”
Citations
Cites
Quantitative estimation of insulin sensitivity.
Bergman, R. N., Ider, Y. Z., Bowden, C. R., & Cobelli, C. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.236.6.e667 · Cited by 1,874
Lyssenko, V., Nagorny, C. L. F., Erdos, M. R., Wierup, N., Jonsson, A., Spégel, P., Bugliani, M., Saxena, R., Fex, M., Pulizzi, N., et al. (2009) · Nature Genetics · doi:10.1038/ng.288 · Cited by 742
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Insulin Causes Endothelial Dysfunction in Humans: Sites and Mechanisms
Arcaro, G., Cretti, A., Balzano, S., Lechi, A., Muggeo, M., Bonora, E., & Bonadonna, R. C. (2002) · Circulation · doi:10.1161/hc0502.103333 · Cited by 407
Endoplasmic reticulum stress and pancreatic β-cell death
Fonseca, S. G., Gromada, J., & Urano, F. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.02.008 · Cited by 384
Black, L. I., Clarke, T. C., Barnes, P. M., Stussman, B. J., & Nahin, R. L. (2015) · PubMed · Cited by 300
Melatonin in type 2 diabetes mellitus and obesity
Karamitri, A., & Jockers, R. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0130-1 · Cited by 268
Gerich, J. E. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s117 · Cited by 264
β-cell failure as a complication of diabetes
Chang-Chen, K. J., Mullur, R., & Bernal-Mizrachi, E. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9101-5 · Cited by 225
Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity
Elahi, D., Nagulesparan, M., Hershcopf, R. J., Muller, D. C., Tobin, J. D., Blix, P. M., Rubenstein, A. H., Unger, R. H., & Andres, R. (1982) · New England Journal of Medicine · doi:10.1056/nejm198205203062002 · Cited by 210
Deacon, S., & Arendt, J. (1995) · Brain Research · doi:10.1016/0006-8993(95)96872-i · Cited by 203
Melatonin effects on glucose metabolism: time to unlock the controversy
Garaulet, M., Qian, J., Florez, J. C., Arendt, J., Saxena, R., & Scheer, F. A. J. L. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.011 · Cited by 193
Self-citationFunction and expression of melatonin receptors on human pancreatic islets
Ramracheya, R. D., Muller, D. S., Squires, P. E., Brereton, H., Sugden, D., Huang, G. C., Amiel, S. A., Jones, P. M., & Persaud, S. J. (2008) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2007.00523.x · Cited by 186
Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening
Rubio-Sastre, P., Scheer, F. A. J. L., Gómez-Abellán, P., Madrid, J. A., & Garaulet, M. (2014) · SLEEP · doi:10.5665/sleep.4088 · Cited by 180
Melatonin, circadian rhythms, and sleep
Arendt, J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010123431510 · Cited by 179
Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene
Mulder, H., Nagorny, C. L. F., Lyssenko, V., & Groop, L. (2009) · Diabetologia · doi:10.1007/s00125-009-1359-y · Cited by 169
Cagnacci, A., Arangino, S., Renzi, A., Paoletti, A. M., Melis, G. B., Cagnacci, P., & Volpe, A. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01232.x · Cited by 139
New evidence for a role of melatonin in glucose regulation
Peschke, E., & Mühlbauer, E. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.09.001 · Cited by 137
Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study
Lopez-Minguez, J., Saxena, R., Bandín, C., Scheer, F. A., & Garaulet, M. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.04.003 · Cited by 124
Self-citationVardi, P., Crisa, L., Jackson, R. A., Dumont Herskowitz, R., Wolfsdorf, J. I., Einhorn, D., Linarelli, L., Dolinar, R., Wentworth, S., Brink, S. J., et al. (1991) · Diabetologia · doi:10.1007/bf00500379 · Cited by 122
Wood, A. R., Jonsson, A., Jackson, A. U., Wang, N., van Leewen, N., Palmer, N. D., Kobes, S., Deelen, J., Boquete-Vilarino, L., Paananen, J., et al. (2017) · Diabetes · doi:10.2337/db16-1452 · Cited by 117
Insulin Suppresses Its Own Secretion In Vivo
Argoud, G. M., Schade, D. S., & Eaton, R. P. (1987) · Diabetes · doi:10.2337/diab.36.8.959 · Cited by 112
Garaulet, M., Gómez-Abellán, P., Rubio-Sastre, P., Madrid, J. A., Saxena, R., & Scheer, F. A. J. L. (2015) · Metabolism · doi:10.1016/j.metabol.2015.08.003 · Cited by 100
Self-citationTrends in Use of Melatonin Supplements Among US Adults, 1999-2018
Li, J., Somers, V. K., Xu, H., Lopez-Jimenez, F., & Covassin, N. (2022) · JAMA · doi:10.1001/jama.2021.23652 · Cited by 97
The interrelationship between sleep, diet, and glucose metabolism
St-Onge, M.-P., Cherta-Murillo, A., Darimont, C., Mantantzis, K., Martin, F. P., & Owen, L. (2023) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2023.101788 · Cited by 79
Garaulet, M., Lopez-Minguez, J., Dashti, H. S., Vetter, C., Hernández-Martínez, A. M., Pérez-Ayala, M., Baraza, J. C., Wang, W., Florez, J. C., Scheer, F. A. J. L., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1314 · Cited by 77
Self-citationPhysiological consequences of phasic insulin release in the normal animal
Cherrington, A. D., Sindelar, D., Edgerton, D., Steiner, K., & McGuinness, O. P. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s103 · Cited by 63
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
Di Giuseppe, G., Ciccarelli, G., Soldovieri, L., Capece, U., Cefalo, C. M. A., Moffa, S., Nista, E. C., Brunetti, M., Cinti, F., Gasbarrini, A., et al. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.02.001 · Cited by 46
Toffolo, G., Cefalu, W. T., & Cobelli, C. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90132-4 · Cited by 37
Critical evaluation of the combined model approach for estimation of prehepatic insulin secretion
Watanabe, R. M., Steil, G. M., & Bergman, R. N. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.274.1.e172 · Cited by 35
Insulin suppresses its own secretion in vivo
Argoud, G., Schade, D. S., & Eaton, R. P. (1987) · Diabetes · doi:10.2337/diabetes.36.8.959 · Cited by 29
Acute metabolic effects of melatonin—A randomized crossover study in healthy young men
Kampmann, U., Lauritzen, E. S., Grarup, N., Jessen, N., Hansen, T., Møller, N., & Støy, J. (2021) · Journal of Pineal Research · doi:10.1111/jpi.12706 · Cited by 24
Li, Y., Huang, T., Redline, S. S., Willett, W. C., Manson, J. E., Schernhammer, E. S., & Hu, F. B. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00096-2 · Cited by 23
Zibolka, J., Mühlbauer, E., & Peschke, E. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12206 · Cited by 21
Melatonin decreases human adipose tissue insulin sensitivity
Zambrano, C., Garitaonaindia, M. T., Salmerón, D., Pérez‐Sanz, F., Tchio, C., Picinato, M. C., de Medina, F. S., Luján, J., Scheer, F. A. J. L., Saxena, R., et al. (2024) · Journal of Pineal Research · doi:10.1111/jpi.12965 · Cited by 10
Self-citationThomaseth, K., Brehm, A., Pavan, A., Pacini, G., & Roden, M. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00314.2013 · Cited by 9
Garaulet, M., Lopez-Minguez, J., Dashti, H. S., Vetter, C., Hernández-Martínez, A. M., Perez‐Ayala, M., Baraza, J. C., Wang, W., Florez, J. C., Scheer, F. A. J. L., et al. (2022) · doi:10.2337/figshare.17122142.v1 · Cited by 6
Self-citationWood, A. R., Jonsson, A. E., Jackson, A., Wang, N., van Leewen, N., Palmer, N. D., Kobes, S., Deelen, J., Vilarino, L. B., Paananen, J., et al. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hwy5-kk80
(1994) · PubMed
Research works printed but not linked: 1
- Phan L , JinY, ZhangH, . ALFA: Allele Frequency Aggregator, 2020. Accessed 22 January 2026. Available from www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/
Metadata
- Authors
- Qian, J., Stefanovski, D., Andersen, P. A. K., Vujovic, N., Kelly, L., Lepson, J., Nguyen, H., Byrne, S., Wang, W., Mandrup-Poulsen, T., Adler, G., Garaulet, M., Saxena, R., & Scheer, F. A. J. L.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Pennsylvania (US)
- Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women’s Hospital 1 , Boston, MA
- University of Copenhagen (DK)
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Qian, Jingyi
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2026-06-25
- Volume
- 49
- Issue
- 8
- Pages
- 1498-1506
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC13385946
- OpenAlex
- W7165915750
- Cited by
- 0
- References
- 31
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Brigham and Women's Hospital (R01 DK102696, R01 HL153969, R01 HL164454, R01 HL167746)
- ADA (1-17-PDF-103, K99 HL 148500, R01 DK102696)
- NIDDK (R01 DK102696)
- Independent Research Fund Denmark (8020-00359B)
- CTSA (UL1RR025758)
- Harvard University
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- melatonin, MTNR1B, type 2 diabetes risk, glucose tolerance, first-phase insulin secretion, insulin sensitivity, insulin-induced hypoglycemia, C-peptide, glucose homeostasis
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucose Tolerance Test, Humans, Insulin, Male, Melatonin, Middle Aged, Cross-Over Studies, Receptor, Melatonin, MT2, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.